Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan

Journal of Managed Care Pharmacy

Volumn 16, Issue 1, 2010, Pages 23-31

  Diehl, Jocelyn L ^a   Daw, Jessica R ^a   Coley, Kim C ^b   Rayburg, Renee ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Clinical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFANT; INJECTION; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAID; MEDICAL SERVICE; NEWBORN; PATIENT COMPLIANCE; PEDIATRICS; PHARMACY; PHYSICIAN; PRESCHOOL CHILD; PRESCRIPTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL BRONCHIOLITIS; VIRUS INFECTION; VIRUS PNEUMONIA;

EID: 76549134735     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.1.23     Document Type: Article

References (22)

1. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J. 2002;21(7):629-32.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543-46.
3. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol. 1991;133(11):1135-51.
4. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-46.
5. McLaurin KK, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1997-2002. Poster presented at: 2005 Pediatric Academic Societies Meeting; May 14-17, 2005; Washington, DC.
6. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127-S132.
7. Centers for Disease Control and Prevention (CDC). Brief report: respiratory syncytial virus activity - United States, July 2007-December 2008. MMWR Morb Mortal Wkly Rep. 2008;57(50):1355-58. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5750a3.htm. Accessed December 17, 2009.
8. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774-93. Available at: http://aappolicy.aappublications.org/cgi/ reprint/pediatrics;118/4/1774.pdf. Accessed on December 17, 2009.
9. MedImmune. Prescribing information. Synagis (palivizumab) for intramuscular injection. March 2009. Available at: http://www.medimmune.com/pdf/ products/synagis-pi.pdf. Accessed December 17, 2009.
10. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531-37.
11. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511-17.
12. Frogel MP, Nerwen C, Boron ML, Cohen AH, Van Veldhuisen PC, Synagis Outcomes Registry Study Group. Impact of Medicaid insurance status among 7,207 infants given RSV monoclonal antibody prophylaxis. Poster presented at: 2003 Pediatric Academic Societies' Annual Meeting; May 5, 2003; Seattle, WA.
13. Langkamp DL and Hlavin SM. Improving compliance with palivizumab. Poster presented at: 2002 APS/SPR/APA Convention; May 4-7, 2002; Baltimore, MD.
14. Mitchell I, Xu J, Johnson D, Johnston D. Compliance study on respiratory syncytial virus (RSV) prevention program. Poster presented at: 2004 ATS Meeting; May 21-26, 2004; Orlando, FL.
15. Langkamp DL, Hlavin SM. Factors predicting compliance with palivizumab in high-risk infants. Am J Perinatol. 2001;18(6):345-52.
16. Weber M, Reno S, Hornbake R, Shillington A. An in-home Synagis program for RSV prevention in high-risk infants. J Manag Care Pharm. 2001;7(6):476-81. Available at: http://www.amcp.org/data/jmcp/Review-476-481. pdf.
17. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3 Pt 1):419-27.
18. Pérez-Yarza EG, Moreno A, Lázaro P, Mejías A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma. A systematic review of the literature. Pediatr Infect Dis J. 2007;26(8):733-39.
19. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161(5):1501-07.
20. Landro L. Weighing which babies get a costly drug: small numbers who benefit may not justify $6,000 price of preventive RSV therapy. Wall Street J. April 16, 2008;D:1. Available at: http://online.wsj.com/public/ article-print/SB120830232791617731.html. Accessed December 17, 2009.
21. Kerr M, Barclay L. New monoclonal antibody effective for RSV prophylaxis in high-risk, full-term infants. Medscape Med News. May 5, 2008. Available at: http://cme.medscape.com/viewarticle/574193?src=rss. Accessed December 17, 2009.
22. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statement - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-701. Available at: http://pediatrics.aappublications.org/cgi/ reprint/peds.2009-2345vl. Accessed December 17, 2009.